Clinica BavieraXMAD:CBAV 100 5-Year Yield-on-Cost % is 2.74 as of Jul. 12, 2026, which is 32% below its 10-year median of 4.02. GuruFocus rates XMAD:CBAV with a GF Score™ of 100/100 and a GF Value™ of €41.41 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 65 Medical Diagnostics & Research companies, Clinica Baviera ranks better than 55.38% on this metric.
Clinica Baviera's yield on cost for the quarter that ended in Mar. 2026 was 2.74.
The historical rank and industry rank for Clinica Baviera's 5-Year Yield-on-Cost % or its related term are showing as below:
XMAD:CBAV'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.55 Med: 4.02 Max: 7.44
Current: 2.74
During the past 13 years, Clinica Baviera's highest Yield on Cost was 7.44. The lowest was 1.55. And the median was 4.02.
XMAD:CBAV's 5-Year Yield-on-Cost % is ranked better than 55.38% of 65
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.45
vs XMAD:CBAV: 2.74
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Clinica Baviera 5-Year Yield-on-Cost % Related Terms
XMAD:CBAV vs TMO, DHR, IDXX: 5-Year Yield-on-Cost % Comparison
For the Diagnostics & Research subindustry, Clinica Baviera's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinica Baviera 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Clinica Baviera's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Clinica Baviera's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Clinica Baviera is calculated as
Clinica Baviera (XMAD:CBAV) has a 5-Year Yield-on-Cost % of 2.74 as of Jul. 12, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Clinica Baviera and its competitors. This is 32% below median its historical median of 4.02. Over the past decade, Clinica Baviera's 5-Year Yield-on-Cost % has ranged from 1.55 to 7.44. According to the industry distribution chart, Clinica Baviera ranks #29 out of 65 companies in the Medical Diagnostics & Research industry, placing it in the top 44.6%.
Is Clinica Baviera's 5-Year Yield-on-Cost % too high?
Clinica Baviera's current 5-Year Yield-on-Cost % of 2.74 is 32% below median its 10-year median of 4.02. Over the past 10 years, this metric has ranged from a low of 1.55 to a high of 7.44. The Medical Diagnostics & Research industry median 5-Year Yield-on-Cost % is 2.45. Clinica Baviera's value of 2.74 is 11.8% above this industry median. Based on the distribution chart, Clinica Baviera ranks #29 out of 65 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Clinica Baviera has a GF Score™ of 100/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clinica Baviera's 5-Year Yield-on-Cost % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Clinica Baviera ranks #29 out of 65 companies for 5-Year Yield-on-Cost %. This puts Clinica Baviera in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.45. Clinica Baviera's value of 2.74 is 11.8% above this benchmark. Historically, Clinica Baviera's own 5-Year Yield-on-Cost % has ranged from 1.55 to 7.44 over the past decade. While the company's 10-year median is 4.02 vs. the industry median of 2.45, Clinica Baviera has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.45, based on 65 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinica Baviera's current 5-Year Yield-on-Cost % of 2.74 is 11.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Clinica Baviera and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinica Baviera's current 5-Year Yield-on-Cost % is 2.74, which is 32% below median its own 10-year median of 4.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinica Baviera stock overvalued right now?
Based on GuruFocus' analysis, Clinica Baviera (XMAD:CBAV) is currently considered Significantly Overvalued. The stock's GF Value™ is €41.41, compared to a current price of €57.40 — trading 38.6% above its estimated fair value. The current 5-Year Yield-on-Cost % is 2.74, which is 32% below median its 10-year median of 4.02 and 11.8% above the Medical Diagnostics & Research industry median of 2.45. Clinica Baviera's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Clinica Baviera (XMAD:CBAV), the current 5-Year Yield-on-Cost % is 2.74 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinica Baviera (XMAD:CBAV) Overvalued in 2026?
Based on GuruFocus' analysis, Clinica Baviera stock appears to be overvalued.
The current stock price of €57.40 is trading 38.6% above its estimated GF Value™ of €41.41.
GuruFocus considers Clinica Baviera to be Significantly Overvalued.
Key valuation signals for XMAD:CBAV:
5-Year Yield-on-Cost %: 2.74 (32% below median its 10-year median of 4.02)
GF Value™: €41.41 vs. price of €57.40 (38.6% above fair value)
Industry Position: 11.8% above the Medical Diagnostics & Research median (#29 of 65)
No single metric tells the full story. See the XMAD:CBAV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinica Baviera SA operates ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. It offers diagnosis and treatment for various eye problems such as long-sightedness, short-sightedness, astigmatism, cataracts and eye strain.
100GF Score
Get the complete analysis for XMAD:CBAV
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:CBAV has been successfully added to your 